.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Conventional deep brain stimulation delivers stimulation using relatively fixed settings, even though Parkinson symptoms and neural activity fluctuate throughout the day. This blinded randomized feasibility trial tested chronic adaptive deep brain stimulation, in which stimulation was adjusted according to patient-specific neural signals. Four people with Parkinson disease received both adaptive and conventional stimulation during crossover testing. The investigators identified neural activity patterns associated with dopaminergic state and residual motor symptoms and used these signals to drive adaptive stimulation. Adaptive DBS improved motor symptoms and quality of life compared with clinically optimised continuous stimulation in this small pilot study. The study is important because it demonstrates a possible path toward truly personalised neuromodulation, but the sample was very small and the findings are not yet sufficient for routine clinical adoption. For HCPs, the main message is translational: future DBS systems may respond dynamically to the patient's neural state rather than relying on fixed programming. Larger trials are needed to establish durability, generalisability, safety and the best biomarkers for control. The work aligns closely with IANCON's interest in advanced neuromodulation and data-driven movement-disorder care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Conventional deep brain stimulation delivers stimulation using relatively fixed settings, even though Parkinson symptoms and neural activity fluctuate throughout the day. This blinded randomized feasibility trial tested chronic adaptive deep brain stimulation, in which stimulation was adjusted according to patient-specific neural signals. Four people with Parkinson disease received both adaptive and conventional stimulation during crossover testing. The investigators identified neural activity patterns associated with dopaminergic state and residual motor symptoms and used these signals to drive adaptive stimulation. Adaptive DBS improved motor symptoms and quality of life compared with clinically optimised continuous stimulation in this small pilot study. The study is important because it demonstrates a possible path toward truly personalised neuromodulation, but the sample was very small and the findings are not yet sufficient for routine clinical adoption. For HCPs, the main message is translational: future DBS systems may respond dynamically to the patient's neural state rather than relying on fixed programming. Larger trials are needed to establish durability, generalisability, safety and the best biomarkers for control. The work aligns closely with IANCON's interest in advanced neuromodulation and data-driven movement-disorder care.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
